The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Next-generation sequencing: revolutionising molecular diagnostics
Lars Bullinger, MD, from the University Hospital of Ulm, Ulm, Germany talks to us about the new technological advancements in research, namely next-generation sequencing, which has revolutionised the field of molecular diagnostics. He mentions that there is a growing need to study molecular markers of diseases such as acute myeloid leukemia (AML), and it would be ideal to integrate these new technologies into the clinical routine of physicians. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
